

Product datasheet

anti-AAV9 (intact particle) mouse recombinant, ADK9-1R,
lyophilized, purified, sample

Short overview

Cat. No.	610178S
Quantity	10 µg
Concentration	50 µg/ml after reconstitution with 200 µl dist. water

Product description

Host	Mouse
Antibody Type	Recombinant
Isotype	IgG1
Clone	ADK9-1R
Immunogen	AAV9 capsids
Formulation	Lyophilized; reconstitute in 200 µl dist. water (final solution contains 0.09% sodium azide, 0.5% BSA in PBS buffer, pH 7.4)
Binding affinity	KD value (AAV9) = <1.0E-12 M
Synonym	Adeno-associated virus 9; AAV-9
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage before reconstitution	2-8°C until indicated expiry date
Storage after reconstitution	Up to 3 months at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
Intended use	Research use only
Application	Dot blot, ELISA, Neutralization assay
Reactivity	AAV9
No reactivity	AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV8, AAVDJ, AAVrh10, AAVrh74

Applications

Dot Blot	1:500 (0.1 µg/ml, non-denaturing conditions)
ELISA	Assay dependent
Neutralization Assay	Assay dependent

Background

For characterization of different stages of infection and very useful for the analysis of the AAV9 assembly process. ADK9-1R specifically reacts with intact AAV9 particles, empty and full capsids. Recognizes a conformational epitope of assembled capsids, not present in denatured capsid proteins and native but unassembled capsid proteins. The antibody cannot be used for immunoblotting. The antibody is also useful for neutralizing experiments. The ADK9-1R antibody recognizes the same epitope as the ADK9 antibody (Cat. No. 690162).

PROGEN Biotechnik GmbH | Maaßstraße 30 | D-69123 Heidelberg

Tel.: +49 (0) 6221 8278-0 | Fax: +49 (0) 6221 8278-24 | Email: info@progen.com | Web: www.progen.com


2024 April 18 / Version: 610178S/DS-070923ibg | Page 1

Limited Use Label License: Research Use OnlyProduct is exclusively owned by PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.


Product images

Antibody clone	Serotype	Binding affinity [KD value]	Neutralization activity [EC50]
ADK9	AAV9	na	~2 ng/ml
ADK9-1R	AAV9	<1.0E-12 M	na
ADK9-h1	AAV9	7.0E-11 M	~8 ng/ml

Comparison of binding affinity and neutralization activity of anti-AAV9 antibodies (mouse monoclonal ADK9, mouse recombinant ADK9-1R and human chimeric ADK9-h1).



Dot blot analysis of native AAV1-AAV9, AAVrh10 capsids (5E+09-5E+10 capsids) and denatured AAV9 capsids (5E+09-5E+10 capsids, denatured at 95°C for 10 min in sample buffer).The nitrocellulose membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV9 (intact particle) mouse recombinant, ADK9-1R (Cat. No. 610178) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Plus Western Blotting Substrate.



Neutralization of AAV9-GFP vectors with the ADK9-1R antibody (Cat. No. 610178). AAV infection was shown in HeLa cells and photos (GFP, CPE, merge) were taken ~48 h post infection. Neutralization was enhanced with increasing ADK9-1R concentration.

References

Publication	Species	Application
Haar, J., Blazevic, D., Strobel, B., Kreuz, S. & Michelfelder, S. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies. Mol. Ther. - Methods Clin. Dev. 25, 360â€“369 (2022).	AAV9	IA